By Lexi Elo
An agreement between Immune Therapeutics and GB Pharma/AHAR with Fidson Healthcare will enable Fidson marketing, sales, customer support, and technical assistance organization to promote Lodonal™ in Nigeria. This will elevate Immune Therapeutics and GB Pharma/AHAR distribution network to the next level. The distribution will become effective, upon completion of the ongoing NAFDAC approved 90‐day Bridging trial evaluating the efficacy and safety of Lodonal™.
Fidson CEO/Managing Director, Dr. Fidelis Ayebae said that, “Fidson is truly excited about this collaboration with Immune Therapeutics and GB Pharma/AHAR. We know that success in this industry going into the future will be dependent on having the right partnerships, and we could not have asked for better partners at this stage of our growth.
“Immune Therapeutics and GB Pharma/AHAR international experience in different markets and their strong commitment to research will be of immense benefit to Fidson. Likewise, Fidson’s towering presence in the Nigeria Pharma space will open a great door for the group to access one of the biggest and most rewarding markets in Africa”.
Fidson Healthcare Plc. recorded sales of $60.5 million in 2014 and has seen revenues rise at a 15% CAGR over the last five years. Its consistent performance in the Nigerian pharmaceutical sector was recently recognized by Frost & Sullivan, who named Fidson as the recipient of its ‘2014 Growth Excellence Leadership Award in the Nigerian Pharmaceutical Industry’.
The Company has also won other corporate awards including the Financial Standard ‘Pharmaceutical Sector Leader’ Award in 2008 and the ‘Nigerian Pharmaceutical Company of the Year’ at the Nigerian Healthcare Excellence Awards (NHEA) in 2014.
To offer options in manufacturing Fidson will be commissioning a $US 54.0 million manufacturing plant in the fourth quarter of 2015. The new facility will double the company’s production capacity. The new factory will also for the first time, add intravenous fluids to Fidson’s product portfolio. The facility is built to conform to the World Health Organization (Geneva) current Good Manufacturing Practice (WHO-GMP) standards.[pro_ad_display_adzone id=”70560″]
AHAR CEO, Dr. Richard Afonja, stated that “we are well positioned to effect this novel approach to treating HIV/AIDS and other immune compromised diseases in the whole of Africa, starting with Nigeria. Bringing Fidson on board will enhance the facilitation of getting this much needed treatment approach for these conditions”.
This announcement comes on the heels of the recent visit [July 20] by Nigerian President Muhammadu Buhari to the White House and President Barack Obama. The significance is monumental as a concrete symbol of US-Nigerian commerce in a non-oil/gas related sector and a show case for the future of local manufacturing of quality pharmaceuticals on the African continent.
President & CEO of GB Pharma, Dr. Gloria B. Herndon, said that; “This is the crescendo of a great masterpiece that partnership of GB Pharma, American Hospitals & Resorts, Immune Therapeutics and Fidson Healthcare, each with its distinct role. Immune Therapeutics, a speciality pharmaceutical company, provides Lodonal™, its patent therapy, in emerging markets.
“GB Pharma is responsible for the introduction of affordable and sustainable healthcare products throughout Africa. AHAR markets and provides the clinical application and promotion through its network. Fidson Healthcare markets and distributes throughout the extensive Nigerian Network.
“We feel that Nigeria and US bilateral relationship will benefit from this amazing initiative that will enhance the health and well-being of people all over the world. This is the spirit of collaboration that President Obama and President Buhari were talking about during the State visit”.
Fidson CEO/Managing Director, Dr. Fidelis Ayebae said that, “Fidson is truly excited about this collaboration with Immune Therapeutics and GB Pharma/AHAR. We know that success in this industry going into the future will be dependent on having the right partnerships, and we could not have asked for better partners at this stage of our growth.
“Immune Therapeutics and GB Pharma/AHAR international experience in different markets and their strong commitment to research will be of immense benefit to Fidson. Likewise, Fidson’s towering presence in the Nigeria Pharma space will open a great door for the group to access one of the biggest and most rewarding markets in Africa”.
Fidson Healthcare Plc. recorded sales of $60.5 million in 2014 and has seen revenues rise at a 15% CAGR over the last five years. Its consistent performance in the Nigerian pharmaceutical sector was recently recognized by Frost & Sullivan, who named Fidson as the recipient of its ‘2014 Growth Excellence Leadership Award in the Nigerian Pharmaceutical Industry’.
The Company has also won other corporate awards including the Financial Standard ‘Pharmaceutical Sector Leader’ Award in 2008 and the ‘Nigerian Pharmaceutical Company of the Year’ at the Nigerian Healthcare Excellence Awards (NHEA) in 2014.
To offer options in manufacturing Fidson will be commissioning a $US 54.0 million manufacturing plant in the fourth quarter of 2015. The new facility will double the company’s production capacity. The new factory will also for the first time, add intravenous fluids to Fidson’s product portfolio. The facility is built to conform to the World Health Organization (Geneva) current Good Manufacturing Practice (WHO-GMP) standards.[pro_ad_display_adzone id=”70560″]
AHAR CEO, Dr. Richard Afonja, stated that “we are well positioned to effect this novel approach to treating HIV/AIDS and other immune compromised diseases in the whole of Africa, starting with Nigeria. Bringing Fidson on board will enhance the facilitation of getting this much needed treatment approach for these conditions”.
This announcement comes on the heels of the recent visit [July 20] by Nigerian President Muhammadu Buhari to the White House and President Barack Obama. The significance is monumental as a concrete symbol of US-Nigerian commerce in a non-oil/gas related sector and a show case for the future of local manufacturing of quality pharmaceuticals on the African continent.
President & CEO of GB Pharma, Dr. Gloria B. Herndon, said that; “This is the crescendo of a great masterpiece that partnership of GB Pharma, American Hospitals & Resorts, Immune Therapeutics and Fidson Healthcare, each with its distinct role. Immune Therapeutics, a speciality pharmaceutical company, provides Lodonal™, its patent therapy, in emerging markets.
“GB Pharma is responsible for the introduction of affordable and sustainable healthcare products throughout Africa. AHAR markets and provides the clinical application and promotion through its network. Fidson Healthcare markets and distributes throughout the extensive Nigerian Network.
“We feel that Nigeria and US bilateral relationship will benefit from this amazing initiative that will enhance the health and well-being of people all over the world. This is the spirit of collaboration that President Obama and President Buhari were talking about during the State visit”.